Search results
90% of U.S. Adults Have This Syndrome That Leads to Heart Disease—and Have No Clue
Prevention· 9 hours agoCardiovascular-kidney-metabolic (CKM) syndrome may affect 90% of U.S. adults, new research finds....
DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?
Zacks via Yahoo Finance· 9 hours agoImage Source: Zacks Investment...Growth The rally in the company’s share price can be attributed to...
Adopting a Wellness Mindset: Kidney Conversations with Dr. Vincent Anthony - Part 3 - Los Angeles...
Los Angeles Sentinel· 6 days agoLAS: How does one discover whether or not he or she has chronic kidney disease? DVA: When you talk about chronic & ...
Unraveling the connection between type 2 diabetes and chronic kidney disease
CBS News· 4 days agoWhen you are newly diagnosed with type 2 diabetes (T2D), many concerns, questions and emotions can...
Horrific nightmares may signal initial onset of these chronic diseases, study says
CNN via Yahoo News· 10 hours agoHorrifying dreams involving murder or being crushed or trapped might be a sign of an emerging...
... Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting -...
Benzinga· 7 days ago"The NKF Spring Clinical Meeting was an important meeting for Unicycive as we were able to present data from the OLC bioequivalence study and our second poster was featured ...
Earnings call: Renalytix reports Q3 results, optimistic on KidneyIntelX By Investing.com
Investing.com· 6 days agoRenalytix, a healthcare company specializing in kidney disease diagnostics, discussed its...
Gastrointestinal Bleeding More Common in Advanced CKD
MedPage Today· 3 days agoRisk was significantly higher regardless of dialysis status
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid...
Digital Journal· 2 days agoVicore plans to progress buloxibutid to Phase 2b development in the first half of this year. Stockholm, May 20, 2024- Vicore Pharma Holding AB (STO: VICO ...
Revelation Biosciences, Inc. (NASDAQ:REVB) to Post Q2 2024 Earnings of ($1.34) Per Share, Roth...
ETF DAILY NEWS· 6 days agoRevelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Investment analysts at Roth Capital raised their Q2 2024 earnings per share (EPS) estimates for shares of Revelation Biosciences in ...